Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0....
Piper Sandler analyst Allison Bratzel maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Overweight and raises the price target f...
Chardan Capital analyst Daniil Gataulin maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Buy and maintains $35 price target.
MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children w...
Raymond James analyst Christopher Raymond initiates coverage on MeiraGTx Hldgs (NASDAQ:MGTX) with a Strong Buy rating and an...
Chardan Capital analyst Daniil Gataulin maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Buy and maintains $35 price target.
MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0....
